1Olson EN,Molkentin JD.Prevention of cardiac hypertrophy by calcineurin inhibition:hope or hype[J]? Circ Res,1999,84(6):623-632.
2Yang K,Mu XS,Xue J J,et al.Increased expression of c-fos mRNA and AP-1 transcription factors after critical impact injury in rat[J].Brain Res,1994,664(12):141-147.
3Hefti MA,Hander BA,Eppenberger,et al.Signaling of pathways in cardiac myocyte hypertrophy[J].J Mol Cell Cardiol,1997,29(11):2873-2892.
4Wilkins BJ,De Windt LJ,Bueno OF,et al.Targeted disruption of NFATc3,but not NFATc4,reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth[J].Mol Cell Biol.2002,22(21):7603-7613.
5Schulz RA,Yutzey KE.Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development[J].Dev Biol,2004,1; 266(1):1-16.
6Patmore L,Whiting RL.Calcium entry blocking properties of Sodium tanshinone ⅡA sulfonate sulphonate,an active principal of the antianginal extract,Danshen[J].Br J Pharmacol,1982,75(suppl):149.
7Xu CQ,Fan JS,Hao XM,et al.Blocking effect of Sodium tanshinone ⅡA sulfonate on L-type Ca^2 + current of single ventricular myocyte from guinea pig[J].Chin J Pharmacol Toxical,1999,10:81-84.
8Piccirillo G, Viola E, Nocco M, et al. Antonomic modulator and QT interval dispersion in hypertensive subjects with anxiety [J]. J Hypertension, 1999, 34: 242-246.
9Sherbourne CD, Jackson CA, Meredith LS, et al. Prevalence of comorbid anxiety discovers in primary care outpatients [J]. J Arch FamMed, 1998, 7: 27-34.
